Ulutin T, Sönmez H, Uçişik N, Süer S, Bayram C, Kökoglu E, Sultuybek G
Genetic and Teratology Research Center, Istanbul University, Cerrahpaşa Medical Faculty, Turkey.
Thromb Res. 1997 Nov 1;88(3):329-32. doi: 10.1016/s0049-3848(97)00262-4.
Endothelial cells, circulating platelets, and proteins of the coagulation and fibrinolytic systems are known to contribute to the hemostatic processes. Various molecular markers of hemostatic alteration are found in increased amounts in the circulation during the activation of this process. In this study, we investigated serum lipoprotein (a) and plasma platelet factor 4, beta-thromboglobulin, thrombin-anthithrombin complex, fibrinopeptid A, D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and fibronectin levels in patients with coronary artery disease. The levels of all these markers were found to be significantly higher as compared to the control group. Our findings suggest that patients with coronary artery disease have greater blood coagulability than controls, and the use of molecular markers has become greatly important in clinical practice.
已知内皮细胞、循环血小板以及凝血和纤溶系统的蛋白质都有助于止血过程。在这一过程激活期间,循环中各种止血改变的分子标志物含量会增加。在本研究中,我们调查了冠心病患者的血清脂蛋白(a)以及血浆血小板因子4、β-血小板球蛋白、凝血酶-抗凝血酶复合物、纤维蛋白肽A、D-二聚体、组织纤溶酶原激活物、组织纤溶酶原激活物抑制剂和纤连蛋白水平。结果发现,与对照组相比,所有这些标志物的水平均显著更高。我们的研究结果表明,冠心病患者的血液凝固性高于对照组,并且分子标志物的应用在临床实践中已变得极为重要。